New and emerging antiarrhythmic drugs for atrial fibrillation: What may become available to the clinician in the near future

Current Treatment Options in Cardiovascular Medicine

Volumn 11, Issue 5, 2009, Pages 373-380

  Kumar, Kapil ^b   Zimetbaum, Peter J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIARRHYTHMIC AND ARRHYTHMIA-INDUCING AGENTS; ATI 2042; BUDIODARONE; CARDIOVASCULAR AGENT; CELIVARONE; DIGOXIN; DOFETILIDE; DRONEDARONE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; LIDOCAINE; PLACEBO; RANOLAZINE; ROTIGAPTIDE; SIMVASTATIN; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; SSR 149744C; UNCLASSIFIED DRUG; VERNAKALANT;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ANTIARRHYTHMIC ACTIVITY; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CREATININE BLOOD LEVEL; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE TACHYCARDIA; HUMAN; LIVER TOXICITY; LUNG TOXICITY; NAUSEA; NEUROTOXICITY; NONHUMAN; RECURRENT DISEASE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SNEEZING; STABLE ANGINA PECTORIS; STRUCTURE ACTIVITY RELATION; SYNCOPE; TASTE; THYROID DISEASE; TORSADE DES POINTES; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

EID: 70349271385     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0038-0     Document Type: Review

References (33)

1. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
2. Van Gelder IC, Hagens VE, Bosker HA, et al.: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834-1840.
3. Roy D, Talajic M, Nattel S, et al.: Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358:2667-2677.
4. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al.: Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007, CD005049.
5. Gautier P, Guillemare E, Marion A, et al.: Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol 2003, 41:191-202.
6. Touboul P, Brugada J, Capucci A, et al.: Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur Heart J 2003, 16:1481-1487.
7. Singh BN, Connolly SJ, Crijns HJ, et al.: Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007, 357:987-999.
8. Davy JM, Herold M, Hoglund C, et al.: Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008, 156:527-529.
9. Sanofi-Aventis: DIONYSOS study results showed the respective profiles of dronedarone and amiodarone [press release]. Available at http://en.sanofi-aventis.com/binaries/ 20081223_dionysos_fe_en_en_tcm28-23624.pdf. Accessed April 26, 2009.
10. Køer L, Torp-Pedersen C, McMurray JJ, et al.: Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008, 358:2678-2687.
11. Tschuppert YT, Buclin T, Rothuizen LE, et al.: Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007, 64:785-791.
12. Hohnloser SH, Crijns HJ, van Eickels M, et al.: Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009, 360:668-678.
13. CoTnolly SJ: ATHENA: the effect of dronedarone on cardiovascular outcomes and stroke in patients with atrial fibrillation. Presented at the European Society of Cardiology Congress. Munich, Germany; September 3, 2008.
14. Gautier P, Guillemare E, Djandjighian L, et al.: In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol 2004, 44:244-257.
15. Kowey PR, Aliot EM, Capucci, et al.: Placebo-controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C in patient with recent atrial fibrillation/flutter [abstract]. Heart Rhythm 2007, 4: 572.
16. NaccarePli GV, Wolbrette DL, Samii S, et al.: Vernakalant: pharmacology electrophysiology, safety and efficacy. Drugs Today (Barc) 2008, 44:325-329.
17. Dorian P, Pinter A, Mangat I, et al.: The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007, 50:35-40.
18. Roy D, Pratt CM, Torp-Pedersen C, et al.: Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation 2008, 117:1518-1525.
19. Roy D, Pratt C, Juul-Moller S, et al.: Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: Results of a phase III, randomized, placebo-controlled, multicenter trial [abstract]. J Am Coll Cardiol 2006, 47:10A.
20. Kowey PR, Roy D, Pratt CM, et al.: Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery [abstract 2860]. Circulation 2007, 116:II-636-II-637.
21. Wettwer E, Hala O, Christ T, et al.: Role of IKur in controlling action potential shape and contractility in the human atrium. Influence of chronic atrial fibrillation. Circulation 2004, 110:2299-2306.
22. Burashnikov A, Antzelevitch C: Can inhibition of IKur promote atrial fibrillation? Heart Rhythm 2008, 5:1304-1309.
23. Belardinelli L, Shryock JC, Fraser H: Inhibition of the late sodium current as a potential cardioprotective principle: Effects of the late sodium current inhibitor ranolazine. Heart 2006, 92:6-14.
24. Chaitman BR: Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006, 113:2462-2472.
25. Burashnikov A, Di Diego JM, Zygmunt AC, et al.: Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007, 116:1449-1457.
26. Kumar K, Nearing BD, Carvas M, et al.: Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 2009 Feb 26 (Epub ahead of print).
27. Sicouri S, Glass A, Belardinelli L, et al.: Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008, 5:1019-1026.
28. Sicouri S, Timothy KW, Zygmunt AC, et al.: Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm 2007, 4:638-647.
29. Antzelevitch C, Belardinelli L, Zygmunt AC, et al.: Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004, 110:904-910.
30. Scirica BM, Morrow DA, Hod H, et al.: Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007, 116:1647-1652.
31. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al.: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial. JAMA 2007, 297:1775-1783.
32. Schoonderwoerd BA, Van GI, Van Veldhuisen DJ, et al.: Electrical and structural remodeling: Role in the genesis and maintenance of atrial fibrillation. Prog Cardiovasc Dis 2005, 48:153-168.
33. Guerra JM, Everett TH, Lee KW, et al.: Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 2006, 114:110-118.